---
title: "Phibro Animal Health | 8-K: FY2026 Q3 Revenue Beats Estimate at USD 383.5 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285437808.md"
datetime: "2026-05-06T20:54:07.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285437808.md)
  - [en](https://longbridge.com/en/news/285437808.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285437808.md)
---

# Phibro Animal Health | 8-K: FY2026 Q3 Revenue Beats Estimate at USD 383.5 M

Revenue: As of FY2026 Q3, the actual value is USD 383.5 M, beating the estimate of USD 367.02 M.

EPS: As of FY2026 Q3, the actual value is USD 0.59, beating the estimate of USD 0.57.

EBIT: As of FY2026 Q3, the actual value is USD 42.7 M.

#### Financial Highlights for the Three Months Ended March 31, 2026

-   Net sales were $383.5 million, an increase of $35.7 million or 10%.
-   Net income was $24.0 million, an increase of $3.1 million or 15%.
-   Adjusted EBITDA was $60.8 million, an increase of $5.9 million or 11%.
-   Adjusted net income was $31.2 million, an increase of $5.0 million or 19%.
-   Gross profit was $125.7 million, an increase of $21.1 million or 20%.
-   Gross margin increased by 270 basis points to 32.8% of net sales, compared to 30.1% in the prior year period.
-   Selling, general and administrative expenses (SG&A) were $81.0 million, an increase of $10.0 million or 14%.
-   Operating income was $44.7 million, an increase of $11.1 million or 33%.
-   Interest expense, net, was $10.4 million, an increase of $1.1 million.
-   Foreign currency losses, net, were $1.9 million, compared to $5.5 million of net gains in the prior year period.
-   Provision for income taxes was $8.3 million, a decrease of -$0.5 million or -6%.
-   The effective income tax rate was 25.7%, compared to 29.7% in the prior year period.
-   The adjusted effective income tax rate was 24.6%, compared to 25.8% in the prior year period.

#### Segment Net Sales for the Three Months Ended March 31, 2026

-   **Animal Health**: Net sales were $291.2 million, an increase of $32.8 million or 13%.
    -   MFAs and other net sales increased by $24.1 million or 13% to $205.8 million.
    -   Nutritional specialty products net sales increased by $3.5 million or 8% to $46.8 million.
    -   Vaccines net sales increased by $5.2 million or 16% to $38.6 million.
-   **Mineral Nutrition**: Net sales were $73.4 million, an increase of $6.6 million or 10%.
-   **Performance Products**: Net sales were $18.9 million, a decrease of -$3.8 million or -17%.

#### Segment Adjusted EBITDA for the Three Months Ended March 31, 2026

-   **Animal Health**: Adjusted EBITDA increased by $8.0 million to $71.1 million.
-   **Mineral Nutrition**: Adjusted EBITDA decreased by -$0.6 million to $5.1 million.
-   **Performance Products**: Adjusted EBITDA decreased by -$1.1 million to $2.2 million.
-   **Corporate**: Corporate expenses increased by -$0.3 million to -$17.7 million.

#### Balance Sheet and Cash Flows (as of or for the twelve months ended March 31, 2026)

-   Free cash flow was $12.8 million for the twelve months ended March 31, 2026.
-   The gross leverage ratio was 3.1x as of March 31, 2026.
-   Total debt was $740.9 million.
-   Adjusted EBITDA for the twelve months ended March 31, 2026, was $240.7 million.
-   Cash and short-term investments were $77.5 million as of March 31, 2026.
-   Phibro Animal Health Corporation’s revolving credit facility was increased by $125 million to an aggregate commitment of $435 million on April 28, 2026.

#### Fiscal Year 2026 Financial Guidance

Phibro Animal Health Corporation updated its fiscal year 2026 guidance, projecting net sales of $1.46 billion to $1.50 billion, net income of $92 million to $100 million, and adjusted EBITDA of $247 million to $255 million. The company also expects diluted EPS of $2.25 to $2.44, adjusted net income of $122 million to $127 million, and an adjusted diluted EPS of $2.98 to $3.10. The adjusted effective tax rate is anticipated to be approximately 25%.

### Related Stocks

- [PAHC.US](https://longbridge.com/en/quote/PAHC.US.md)

## Related News & Research

- [Phibro Animal Health posts transcript of Q3 2026 earnings call](https://longbridge.com/en/news/287102335.md)
- [Phibro Animal Health's (PAHC) CEO Sold 21,120 Shares for $1.2 Million](https://longbridge.com/en/news/284413857.md)
- [SEAWORLD REACHES MILESTONE OF 43,000 ANIMAL RESCUES, UNDERSCORING THE ONGOING NEED TO HELP ANIMALS IN NEED | PRKS Stock News](https://longbridge.com/en/news/286771887.md)
- [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md)
- [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md)